Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth

BACKGROUND: The monoclonal antibody daratumumab, approved for treating myeloma, targets CD38, a protein on myeloma and also on CD34+ hematopoietic progenitor cells. Because mobilized CD34+ cells are critical for stem cell transplant, we investigated the in vitro activity of daratumumab on mobilized...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Exp Hematol Oncol
Main Authors: Ma, Xun, Wong, Sandy W., Zhou, Ping, Chaulagain, Chakra P., Doshi, Parul, Klein, Andreas K., Sprague, Kellie, Kugelmass, Adin, Toskic, Denis, Warner, Melissa, Miller, Kenneth B., Lee, Lisa, Varga, Cindy, Comenzo, Raymond L.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2018
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6192105/
https://ncbi.nlm.nih.gov/pubmed/30356940
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-018-0119-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados